ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z.

Abstract

A European consensus conference on endometrial carcinoma was held in 2014 to produce multidisciplinary evidence-based guidelines on selected questions. Given the large body of literature on the management of endometrial carcinoma published since 2014, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) jointly decided to update these evidence-based guidelines and to cover new topics in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide. ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of endometrial carcinoma (27 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2014, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 191 independent international practitioners in cancer care delivery and patient representatives. The guidelines comprehensively cover endometrial carcinoma staging, definition of prognostic risk groups integrating molecular markers, pre- and intra-operative work-up, fertility preservation, management for early, advanced, metastatic, and recurrent disease and palliative treatment. Principles of radiotherapy and pathological evaluation are also defined.

Keywords: Endometrial carcinoma; Guidelines; Management; Molecular markers; Staging.

Publication types

  • Consensus Development Conference
  • Practice Guideline
  • Systematic Review

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biopsy / standards
  • Carcinoma / genetics
  • Carcinoma / pathology
  • Carcinoma / therapy*
  • Endometrial Neoplasms / genetics
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy*
  • Evidence-Based Medicine / standards
  • Female
  • Humans
  • Medical Oncology / standards*
  • Molecular Diagnostic Techniques / standards
  • Neoplasm Staging / standards
  • Predictive Value of Tests
  • Risk Assessment
  • Risk Factors
  • Treatment Outcome

Substances

  • Biomarkers, Tumor